| CTRI Number |
CTRI/2026/02/103516 [Registered on: 10/02/2026] Trial Registered Prospectively |
| Last Modified On: |
10/02/2026 |
| Post Graduate Thesis |
No |
| Type of Trial |
Observational |
|
Type of Study
|
Cohort Study |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
A Prospective Observational Study of a Lung Cancer Registry |
|
Scientific Title of Study
|
A Prospective Observational Study of a Cancer Registry for all Lung Cancer Patients |
| Trial Acronym |
LUNG_REGISTRY |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| LUNGREGISTRY/MOC/version2/070226 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Udip Maheshwari |
| Designation |
Consultant Medical Oncologist |
| Affiliation |
MOC Cancer Care and Research Centre |
| Address |
Address: MOC Cancer Care and Research Centre, Consultant Room 1, Silver Point, 8th, Lal Bahadur Shastri Marg, opp. Sukhshanti Hospital, Kasturi Park, Maneklal Estate, Ghatkopar West, Mumbai, Maharashtra 400086
Same as above
Mumbai
MAHARASHTRA
400086
India |
| Phone |
7677434237 |
| Fax |
|
| Email |
drudipdm@mocindia.co.in |
|
Details of Contact Person
Scientific Query
|
| Name |
Dr Udip Maheshwari |
| Designation |
Consultant Medical Oncologist |
| Affiliation |
MOC Cancer Care and Research Centre |
| Address |
Address: MOC Cancer Care and Research Centre, Consultant Room 1, Silver Point, 8th, Lal Bahadur Shastri Marg, opp. Sukhshanti Hospital, Kasturi Park, Maneklal Estate, Ghatkopar West, Mumbai, Maharashtra 400086
Same as above
Mumbai
MAHARASHTRA
400086
India |
| Phone |
7677434237 |
| Fax |
|
| Email |
drudipdm@mocindia.co.in |
|
Details of Contact Person
Public Query
|
| Name |
Dr Udip Maheshwari |
| Designation |
Consultant Medical Oncologist |
| Affiliation |
MOC Cancer Care and Research Centre |
| Address |
Address: MOC Cancer Care and Research Centre, Consultant Room 1, Silver Point, 8th, Lal Bahadur Shastri Marg, opp. Sukhshanti Hospital, Kasturi Park, Maneklal Estate, Ghatkopar West, Mumbai, Maharashtra 400086
Same as above
Mumbai
MAHARASHTRA
400086
India |
| Phone |
7677434237 |
| Fax |
|
| Email |
drudipdm@mocindia.co.in |
|
|
Source of Monetary or Material Support
|
| MOC Cancer Care and Research Centre
|
|
|
Primary Sponsor
|
| Name |
MOC Cancer Care and Research Centre |
| Address |
Silver Point, 8th, Lal Bahadur Shastri Marg, opp. Sukhshanti Hospital, Kasturi Park, Maneklal Estate, Ghatkopar West, Mumbai, Maharashtra 400086 |
| Type of Sponsor |
Research institution |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Udip Maheshwari |
MOC Cancer Care and Research Centre Ghatkopar |
Address: MOC Cancer Care and Research Centre, Consultant Room 1, Silver Point, 8th, Lal Bahadur Shastri Marg, opp. Sukhshanti Hospital, Kasturi Park, Maneklal Estate, Ghatkopar West, Mumbai, Maharashtra 400086
Same as above
Mumbai
MAHARASHTRA |
07677434237
drudipdm@mocindia.co.in |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Mumbai Oncocare Centre Institutional Ethics Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: C348||Malignant neoplasm of overlappingsites of bronchus and lung, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Nil |
Nil |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
85.00 Year(s) |
| Gender |
Both |
| Details |
1. All lung cancer patient’s confirmed histologically.
Age more than 18 years.
Gender: Male or Female.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 4.
Ability to provide written informed consent and comply with collection and storage of data.
|
|
| ExclusionCriteria |
| Details |
Failure to provide informed consent and comply with collection and storage of data. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To build a comprehensive database of all lung cancer cases thereby providing a long-term resource. |
at baseline and then follow up every month and 3 months |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To evaluate the long-term survival rates and the lasting effects of treatment by tracking patients for long periods. Quality of Life (QOL) was assessed by validated questionnaires. |
at baseline and completion of treatment. |
|
|
Target Sample Size
|
Total Sample Size="1000"
Sample Size from India="1000"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
23/02/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="3"
Months="0"
Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
The cancer registry is a data information system, which aims to systematically collect, store, manage and analyse data of all lung cancer cases across cancer centers in Mumbai. This prospective observational study seeks to build and create a comprehensive and well-organized lung cancer registry, which will be helpful in consolidating and generating robust and accurate patient data at all-time points. Large, comprehensive datasets from registries allow researchers to study cancer more effectively, leading to an understanding of its causes, progression, and effective treatments. The registry then can serve as a valuable resource of information for all future studies.
|